AbbVie Inc. ABBV NYSE

AbbVie Inc. (ABBV) generated $19.03B in operating cash flow for fiscal year 2025. After capital expenditures of $1.21B, free cash flow was $17.82B.

Free cash flow margin was 29.1% of revenue. Cash conversion ratio was 4.5x, indicating earnings are backed by cash.

The company returned $11.66B in dividends and $980M in share buybacks to shareholders during the period.

Criteria supported by this page:

• HEALTH (50/100, Partial) — cash generation is adequate but may not fully cover debt in stressed conditions
• MOAT (94/100, Pass) — $17.82B (29.1% FCF margin) supports a durable competitive advantage
• INCOME (45/100) — Cash conversion ratio was 4.5x confirms earnings are backed by real cash flow

Overall SharesGrow Score: 61/100 with 3/7 criteria passed.